HIV-1 disease progression during highly active antiretroviral therapy: An application using population-level data in British Columbia: 1996-2011

Journal of Acquired Immune Deficiency Syndromes

Volumn 63, Issue 5, 2013, Pages 653-659

  Nosyk, Bohdan ^a,b   Min, Jeong ^a   Lima, Viviane D ^a,c   Yip, Benita ^a   Hogg, Robert S ^a,b   Montaner, Julio S G ^a,c  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Acquired immune deficiency syndromes; CD4; Human immunodeficiency virus; Multi state Markov models; Transition probabilities

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; VIRUS LOAD;

EID: 84883319216     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182976891     Document Type: Article

References (43)

1. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954.
2. Moss AR, Bacchetti P. Natural history of HIV infection. AIDS. 1989;3: 55-61.
3. Antiretroviral Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-299.
4. Carpenter CJC, Fischl MA, Hammer SM, et al. Antiretroviral Therapy for HIV Infection in 1996. JAMA. 1996;276:146-154.
5. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308:387-402.
6. Binquet C, Le Teuff C, Abrahamovicz M, et al, for the Groupe Inter-COrevih du Nord-Est (ICONE). Markov modeling of HIV infection evolution in the HAART era. Epidemiol Infect. 2009;137:1272-1282.
7. Sterne J, Hernán MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366:378-384.
8. Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory With Practice. Oxford, United Kingdom: Oxford University Press; 2001.
9. Ramsey S, Willke R, Briggs A, et al. Good research practices for costeffectiveness analysis alongside clinical trials: the ISPOR RCT-CEA task force report. Value Health. 2005;8:521-533.
10. Walensky RP, Freedberg KA, Weinstein MC, et al. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45: S248-S254.
11. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153:778-789.
12. Long EF, Brandeau ML, Galvin CM, et al. Effectiveness and costeffectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS. 2006;20:2207-2215.
13. Sanders GD, Bayoumi AM, Sundaram V, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-585.
14. Mauskopf J, Kitahata M, Kauf T, et al. HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr. 2005;39:562-569.
15. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6:171-177.
16. Barnett PG, Chow A, Joyce VR, et al, for the OPTIMA team. Determinants of the costs of health services used by veterans with HIV. Med Care. 2011;49:848-856.
17. Levy A, Johnston K, Annemans L, et al. The impact of disease stage on direct medical costs of HIV management: a review of the international literature. Pharmacoeconomics. 2010;28(suppl 1):35-47.
18. Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health. 2008;11:1144-1153.
19. Anis AH, Nosyk B, Sun H, et al; for the OPTIMA Team. Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr. 2009;51:631-639.
20. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care: Merging Theory With Practice. Oxford, United Kingdom: Oxford University Press; 2001:172-214.
21. Mauskopf J, Annemans L, Hill AM, et al. A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection. Pharmacoeconomics. 2010;28(suppl 1): 1-16.
22. Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005;39:69-77.
23. Alioum A, Leroy V, Commenges D, et al. Effect of gender, age, transmission category, and antiretroviral therapy on the progression of human immunodeficiency virus infection using multistate Markov models. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Epidemiology. 1998;9:605-612.
24. Nichol MB, Knight TK, Wu J, et al. Transition probabilities and predictors of adherence in a California Medicaid population using antihypertensive and lipid-lowering medications. Value Health. 2009;12:544-550.
25. Borg S, Persson U, Jess T, et al. A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations. Med Decis Making. 2010;30:132-142.
26. Alexander CS, Montessori V, Wynhoven B, et al. Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antivir Ther. 2002;7:31-35.
27. Hoover DR, Graham NM, Chen B, et al. Effect of CD4+ cell count measurement variability on staging HIV-1 infection. J Acquir Immune Defic Syndr. 1992;5:794-802.
28. Sypsa V, Touloumi G, Kenward M, et al. Comparison of smoothing techniques for CD4 data in a Markov model with states defined by CD4: an example on the estimation of the HIV incubation time distribution. Stat Med. 2001;20:3667-3676.
29. Guihenneuc-Jouyaux C, Richardson S, Longini IM Jr. Modeling markers of disease progression by a hidden Markov process: application to characterizing CD4 cell decline. Biometrics. 2000;56:733-741.
30. Mathieu E, Loup P, Dellamonica P, et al. Markov modelling of immunological and virological states in HIV-1 infected patients. Biom J. 2005; 47:834-846.
31. Charitos T, de Waal PR, van der Gaag LC. Computing short-interval transition matrices of a discrete-time Markov chain from partially observed data. Stat Med. 2008;27:905-921.
32. Satten GA, Longini IM. Markov chains with measurement error: estimating the "true" course of a marker of the progression of the human immunodeficiency virus disease. Appl Stat. 1996;45:275-309.
33. Craig BA, Sendi PP. Estimation of the transition matrix of a discrete-time Markov chain. Health Econ. 2002;11:33-42.
34. Cox D. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;B34:187-220.
35. Grujer J, Kay R, Schumacher M. The validity of inferences based on incomplete observations in disease state models. Biometrics. 1991;47: 595-605.
36. Sweeting MJ, Farewell VT, De Angelis D. Multi-state Markov models for disease progression in the presence of informative examination times: an application to hepatitis C. Stat Med. 2010;29:1161-1174.
37. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
38. Jackson CH. Multi-state models for panel data: the msm package for R. J Stat Softw. 2011;38:1-29.
39. MSM. Multi-state Markov and hidden Markov models in continuous time. Available at: http://cran.r-project.org/web/packages/msm/index. html. Accessed April 2, 2012.
40. Herbeck JT, Gottlieb GS, Li X, et al. Lack of evidence for changing virulence of HIV-1 in North America. PLoS One. 2008;3:e1525.
41. Granich R, Gupta S, Suthar A, et al, on behalf of the ART in Prevention of HIV and TB Research Writing Group. ART in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011;9:446-469.
42. Bland S. The global fund is alive and well, but global health progress is in peril. The Global Fund to fight AIDS, Tuberculosis and Malaria. Available at: http://www.theglobalfund.org/en/mediacenter/announcements/2011-12-01-The- Global-Fund-is-alive-and-well-But-Global-Health-Progress-is-in-Peril-by-Simon- Bland-the-Chair-of-the-Board-of-the-Global-Fund/. Accessed September 6, 2012.
43. Lima VD, Harrigan PR, Sénécal M, et al. Epidemiology of antiretroviral multiclass resistance. Am J Epidemiol. 2010;172:460-468.